Liquidia Technologies
General Information | |
Business: |
We are a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. We are currently focused on the development of two product candidates for which we hold worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension, or PAH, and LIQ865 for the treatment of local post-operative pain. Our lead product candidate, LIQ861, is being evaluated in a Phase 3 trial. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies. |
Industry: | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
Employees: | 60 |
Founded: | 2004 |
Contact Information | |
Address | 419 Davis Drive, Suite 100, Morrisville, NC 27560, US |
Phone Number | (919) 328-4400 |
Web Address | http://www.liquidia.com |
View Prospectus: | Liquidia Technologies |
Financial Information | |
Market Cap | $166.3mil |
Revenues | $6.5 mil (last 12 months) |
Net Income | $-46.8 mil (last 12 months) |
IPO Profile | |
Symbol | LQDA |
Exchange | NASDAQ |
Shares (millions): | 4.5 |
Price range | $11.00 - $11.00 |
Est. $ Volume | $50.0 mil |
Manager / Joint Managers | Jefferies/ Cowen |
CO-Managers | Needham & Company/ Wedbush PacGrow |
Expected To Trade: | 7/26/2018 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |